These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 31713478)
1. Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination. Zareian N; Aprile S; Cristaldi L; Ligotti ME; Vasto S; Farzaneh F Curr Pharm Des; 2019; 25(39):4163-4167. PubMed ID: 31713478 [TBL] [Abstract][Full Text] [Related]
2. How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells. Aiello A; Ligotti ME; Garnica M; Accardi G; Calabrò A; Pojero F; Arasanz H; Bocanegra A; Blanco E; Chocarro L; Echaide M; Fernandez-Rubio L; Ramos P; Piñeiro-Hermida S; Kochan G; Zareian N; Farzaneh F; Escors D; Caruso C; Candore G Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077278 [TBL] [Abstract][Full Text] [Related]
3. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Maisonneuve C; Bertholet S; Philpott DJ; De Gregorio E Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12294-9. PubMed ID: 25136133 [TBL] [Abstract][Full Text] [Related]
4. Toll-like receptors in older adults. van Duin D; Shaw AC J Am Geriatr Soc; 2007 Sep; 55(9):1438-44. PubMed ID: 17767688 [TBL] [Abstract][Full Text] [Related]
5. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB Front Immunol; 2020; 11():615240. PubMed ID: 33679703 [TBL] [Abstract][Full Text] [Related]
6. In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. van Haren SD; Ganapathi L; Bergelson I; Dowling DJ; Banks M; Samuels RC; Reed SG; Marshall JD; Levy O Cytokine; 2016 Jul; 83():99-109. PubMed ID: 27081760 [TBL] [Abstract][Full Text] [Related]
7. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination. Shen CF; Yen CL; Fu YC; Cheng CM; Shen TC; Chang PD; Cheng KH; Liu CC; Chang YT; Chen PL; Ko WC; Shieh CC Front Immunol; 2022; 13():807454. PubMed ID: 35145520 [TBL] [Abstract][Full Text] [Related]
8. Toll-like Receptor function of murine macrophages, probed by cytokine induction, is biphasic and is not impaired globally with age. Pattabiraman G; Palasiewicz K; Ucker DS Mech Ageing Dev; 2016 Jul; 157():44-59. PubMed ID: 27453067 [TBL] [Abstract][Full Text] [Related]
9. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS Front Immunol; 2020; 11():1112. PubMed ID: 32595636 [TBL] [Abstract][Full Text] [Related]
10. Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses. Madan-Lala R; Pradhan P; Roy K Sci Rep; 2017 May; 7(1):2530. PubMed ID: 28566683 [TBL] [Abstract][Full Text] [Related]
12. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Lahiri A; Das P; Chakravortty D Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576 [TBL] [Abstract][Full Text] [Related]
13. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Black M; Trent A; Tirrell M; Olive C Expert Rev Vaccines; 2010 Feb; 9(2):157-73. PubMed ID: 20109027 [TBL] [Abstract][Full Text] [Related]
14. The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age. Weinberger B; Joos C; Reed SG; Coler R; Grubeck-Loebenstein B Biogerontology; 2016 Feb; 17(1):177-87. PubMed ID: 25957253 [TBL] [Abstract][Full Text] [Related]